These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

990 related articles for article (PubMed ID: 32817083)

  • 1. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
    Gong H; Nie D; Huang Y; Li Z
    Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
    Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
    Ruscito I; Bellati F; Ray-Coquard I; Mirza MR; du Bois A; Gasparri ML; Costanzi F; De Marco MP; Nuti M; Caserta D; Pignata S; Dorigo O; Sehouli J; Braicu EI
    Cancer Treat Rev; 2020 Jul; 87():102040. PubMed ID: 32485510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    Foote JR; Secord AA; Liang MI; Ehrisman JA; Cohn DE; Jewell E; Havrilesky LJ
    Gynecol Oncol; 2019 Mar; 152(3):445-451. PubMed ID: 30876487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with
    Zhou S; Jiang Y; Luo C; Yuan L
    Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
    Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
    [No Abstract]   [Full Text] [Related]  

  • 8. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations.
    Vanacker H; Harter P; Labidi-Galy SI; Banerjee S; Oaknin A; Lorusso D; Ray-Coquard I
    Cancer Treat Rev; 2021 Sep; 99():102255. PubMed ID: 34332292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
    Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    Lee EK; Matulonis UA
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials.
    Baradács I; Teutsch B; Váradi A; Bilá A; Vincze Á; Hegyi P; Fazekas T; Komoróczy B; Nyirády P; Ács N; Bánhidy F; Lintner B
    J Ovarian Res; 2024 Feb; 17(1):53. PubMed ID: 38409030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
    Madariaga A; Bowering V; Ahrari S; Oza AM; Lheureux S
    Int J Gynecol Cancer; 2020 Jul; 30(7):903-915. PubMed ID: 32276934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
    Smith M; Pothuri B
    Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Eakin CM; Ewongwo A; Pendleton L; Monk BJ; Chase DM
    Gynecol Oncol; 2020 Oct; 159(1):112-117. PubMed ID: 32811682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
    Tew WP; Lacchetti C; Ellis A; Maxian K; Banerjee S; Bookman M; Jones MB; Lee JM; Lheureux S; Liu JF; Moore KN; Muller C; Rodriguez P; Walsh C; Westin SN; Kohn EC
    J Clin Oncol; 2020 Oct; 38(30):3468-3493. PubMed ID: 32790492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
    Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
    Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
    Pujade-Lauraine E; Selle F; Scambia G; Asselain B; Marmé F; Lindemann K; Colombo N; Mądry R; Glasspool R; Vergote I; Korach J; Lheureux S; Dubot C; Oaknin A; Zamagni C; Heitz F; Gladieff L; Rubio-Pérez MJ; Scollo P; Blakeley C; Shaw B; Ray-Coquard I; Redondo A;
    Ann Oncol; 2023 Dec; 34(12):1152-1164. PubMed ID: 37797734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis.
    Huang Y; He H; Liang L; Zhang Y; Peng K; Wang Y; Wu J; Long X; Kairemo K; Goldberg H; Mendez LC; Gu D
    Chin Clin Oncol; 2024 Aug; 13(4):64. PubMed ID: 39238347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.